Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1866 1
1873 1
1874 1
1890 1
1912 1
1932 1
1955 2
1964 1
1965 1
1975 1
1985 1
1987 1
1988 1
1989 1
1990 1
1992 1
1993 1
1998 1
1999 1
2002 1
2005 2
2006 1
2007 2
2008 4
2009 6
2010 4
2011 11
2012 15
2013 15
2014 16
2015 32
2016 34
2017 29
2018 21
2019 13
2020 20
2021 18
2022 14
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27457311

226 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH; GO-MORE Investigators. Combe B, et al. Ann Rheum Dis. 2014 Aug;73(8):1477-86. doi: 10.1136/annrheumdis-2013-203229. Epub 2013 Jun 5. Ann Rheum Dis. 2014. PMID: 23740226 Free PMC article. Clinical Trial.
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A, Schulze-Koops H, Durez P, Wolff V, Yao R, Weng HH, Govoni M, Vastesaeger N. Dasgupta B, et al. Arthritis Care Res (Hoboken). 2014 Dec;66(12):1799-807. doi: 10.1002/acr.22371. Arthritis Care Res (Hoboken). 2014. PMID: 24839031 Free article. Clinical Trial.
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
Alonso A, González CM, Ballina J, García Vivar ML, Gómez-Reino JJ, Marenco JL, Fernández-Nebro A, Ordás C, Cea-Calvo L, Arteaga MJ, Sanmartí R. Alonso A, et al. Reumatol Clin. 2015 May-Jun;11(3):144-50. doi: 10.1016/j.reuma.2014.05.002. Epub 2014 Jul 10. Reumatol Clin. 2015. PMID: 25022442 Free article. Clinical Trial.
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Bingham CO 3rd, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME; GO-FURTHER Investigators. Bingham CO 3rd, et al. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1627-36. doi: 10.1002/acr.22556. Arthritis Care Res (Hoboken). 2015. PMID: 25623393 Free PMC article. Clinical Trial.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators. Smolen JS, et al. Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Lancet. 2009. PMID: 19560810 Clinical Trial.
226 results